Guo-wu Yin

Fourth Military Medical University, Xi’an, Liaoning, China

Are you Guo-wu Yin?

Claim your profile

Publications (8)18.41 Total impact

  • F Jiang · Y Yang · J Li · W Li · Y Luo · Y Li · H Zhao · X Wang · G Yin · G Wu ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Preeclampsia is major cause of maternal and fetal morbidity and mortality. Currently, the etiology of preeclampsia is unclear. In this study, we investigated differences in gene expression between preeclampsia patients and controls using partial least squares-based analysis, which is more suitable than routine analysis. Expression profile data were downloaded from the Gene Expression Omnibus database. A total of 503 genes were found to be differentially expressed, including 248 downregulated genes and 255 overexpressed genes. Network analysis identified 5 hub genes, including UBB, PIK3R1, MAPRE1, VEGFA, and ITGB1. Three of these, PIK3R1, VEGFA, and ITGB1, are known to be associated with preeclampsia or preeclampsia-related biological processes. Our findings shed light on expression signatures of preeclampsia patients that can be used as theoretical support in future therapeutic studies.
    Genetics and molecular research: GMR 06/2015; 14(2):6598-6604. DOI:10.4238/2015.June.18.2 · 0.78 Impact Factor
  • M Long · G Yin · L Liu · F Lin · X Wang · J Ren · J Wei · K Dong · H Zhang ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Aurora A has multiple key functions in tumor initiation and progression and is overexpressed in many cancers. Several ongoing clinical trials are assessing the unique therapeutic potential of Aurora-based targeted therapy, but several severe adverse events such as hematopoietic toxicity have been observed in the early-phase clinical trials because Aurora A is also involved in normal cells proliferation process. The strategy to develop tumor-specific inhibition of this target may be an alteration for the treatment of Aurora A overexpression tumors. In this study, we developed a novel tumor-specific RNA interference adenovirus system targeting Aurora A by using stathmin promoter and investigated the effects of it on the proliferation, apoptosis and chemotherapy sensitivity in human breast carcinoma cells both in vitro and in vivo. The results showed that treatment of human breast carcinoma cells (SK-BR-3 and MDA-MB-231) by Aurora A short hairpin RNA (shRNA) driven by stathmin gene promoter not only inhibited the cells proliferation, but also enhanced the chemosensitivity to paclitaxel via downregulation of Aurora A mRNA and protein expression, which further decreased the phosphatidylinositol 3 kinase/Akt and p-BRCA1 protein expression. Furthermore, there were no obvious phenotypes changes observed in normally differentiated epithelial cells of MCF210. Therefore, stathmin promoter-driving Aurora A shRNA adenoviral system may have potential use, with targeted tumor gene silencing effect and as adjuvant tumor-specific therapy method, in the treatment of human breast carcinomas.
    Cancer gene therapy 01/2012; 19(4):271-81. DOI:10.1038/cgt.2011.89 · 2.42 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Reprogramming human somatic cells to pluripotency represents a valuable resource for research aiming at the development of in vitro models for human diseases and regenerative medicines to produce patient-specific induced pluripotent stem (iPS) cells. Seeking appropriate cell resources for higher efficiency and reducing the risk of viral transgene activation, especially oncogene activation, are of significance for iPS cell research. In this study, we tested whether human amnion-derived cells (hADCs) could be rapidly and efficiently reprogrammed into iPS cells by the defined factors: OCT4/SOX2/NANOG. hADCs from normal placenta were isolated and cultured. The 3rd passage cells were infected with the lentiviral vectors for the delivery of OCT4, SOX2, and NANOG. Afterwards, the generated iPSCs were identified by morphology, pluripotency markers, global gene expression profiles, and epigenetic status both in vitro and in vivo. The results showed that we were able to reprogram hADCs by the defined factors (OCT4/SOX2/NANOG). The efficiency was significantly high (about 0.1%), and the typical colonies appeared on the 9th day after infection. They were similar to human embryonic stem (ES) cells in morphology, proliferation, surface markers, gene expression, and the epigenetic status of pluripotent cell-specific genes. Furthermore, these cells were able to differentiate into various cell types of all three germ layers both in vitro and in vivo. These results demonstrate that hADCs were an ideal somatic cell resource for the rapid and efficient generation of iPS cells by OCT4/SOX2/NANOG.
    Differentiation 09/2010; 80(2-3):123-9. DOI:10.1016/j.diff.2010.03.002 · 3.44 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of this study was to gain a further understanding of the relationship between miR-152 and human leukocyte antigen (HLA)-G in human trophoblast cell line (JEG-3). The JEG-3 cells were transfected with pre-miR-152. The effect of the overexpressed miR-152 on HLA-G expression, trophoblast invasion, and natural killer (NK) cell-mediated cytolysis were assessed by reverse-transcription polymerase chain reaction (RT-PCR) and Western blot analysis, transwell invasion assay, and NK cell cytotoxicity assay, respectively. The miR-152 repressed HLA-G expression but exerted no effect on JEG-3 cell invasion, and overexpression of miR-152 led to increased NK cell-mediated cytolysis in JEG-3 cells. The data indicate that miR-152 may function as an immune system enhancer through up-regulating NK cell-mediated cytolysis of host cells.
    American journal of obstetrics and gynecology 06/2010; 202(6):592.e1-7. DOI:10.1016/j.ajog.2010.03.002 · 4.70 Impact Factor
  • Source
    Xiao-ming Zhu · Tao Han · Ian L Sargent · Guo-wu Yin · Yuan-qing Yao ·
    [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of this study was to perform a comprehensive analysis of the microRNA expression profile in placentas from preeclamptic pregnancies vs normal placentas. Placentas were obtained from patients with (1) mild preeclampsia (n = 8) and (2) severe preeclampsia (n = 15) and (3) in a normal control group (n = 11) with elective cesarean delivery. The microRNA expression profile was assessed by microRNA microarray and real-time reverse transcriptase-polymerase chain reaction analysis. Thirty-four microRNAs were expressed differentially in preeclamptic placentas, compared with normal placentas. Of these, 11 microRNAs were overexpressed, and 23 microRNAs were underexpressed in preeclamptic pregnancies. Notably, several microRNA clusters on human chromosome 19q13.42, 13q31.3, Xq26.2, Xq26.3, and 14q32.31 (a human imprinted region) were expressed differentially in preeclamptic placentas. These results were confirmed with the use of real-time polymerase chain reaction for selected microRNAs (miR-210, -152, -411, and so on). The results show that 34 microRNAs are deregulated in preeclamptic pregnancies, which suggests the involvement of these microRNAs in the pathogenesis of preeclampsia.
    American journal of obstetrics and gynecology 04/2009; 200(6):661.e1-7. DOI:10.1016/j.ajog.2008.12.045 · 4.70 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To identify gene expression profiling in epithelial ovarian cancer and to explore its correlation with histopathology characterization and prognosis. Gene expression profiles were generated from 10 human ovarian frozen tissue specimens using Agilent Human 1A microarrays. Strikingly, clear differences of gene expression patterns were observed in ovarian cancer as compared to normal tissues. Unique gene profiles were observed in moderately and poorly differentiated epithelial ovarian cancer. It is concluded that different histopathology characterization likely exists extensive molecular heterogeneity.
    Journal of Medical Colleges of PLA 12/2007; 22(6):373-375. DOI:10.1016/S1000-1948(08)60021-0
  • [Show abstract] [Hide abstract]
    ABSTRACT: To investigate the expression of hypoxia inducible factor-1alpha (HIF-1alpha) in placentas of pregnancy induced hypertension (PIH). Placentas of 49 PIH pregnancies (PIH group 1) and 26 normotensive pregnancies (control group 1) were investigated for HIF-1alpha protein expression using microarray and immunohistochemistry. The expression of HIF-1alpha mRNA in placentas of 12 PIH pregnancies (PIH group 2) and 12 normal pregnancies(control group 2) was respectively detected by RT-PCR. (1) There was significant difference in the positive and slight-moderate-positive spot proportions of HIF-1alpha protein between the PIH group 1 (63.1%, 23.3%) and the control group 1 (20.9%, 7.0%, P < 0.01). (2) The level of HIF-1alpha mRNA between PIH group 2 and control group 2 (0.96 +/- 0.37 vs 0.95 +/- 0.20, P > 0.05) was not statistically different. (1) There was no significant difference in HIF-1alpha mRNA level between the PIH and normal placentas, but there was a remarkable difference in protein level between the two groups. (2) HIF-1alpha regulate the pathological and physiological progress of PIH at protein level rather than at transcription level.
    Zhonghua fu chan ke za zhi 07/2004; 39(7):442-5.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To sum up the experience of the successful therapy for the severe hepatitis of pregnant woman with postpartum massive hemorrhage. The advanced therapeutic methods including the bilateral uterine artery embolism, hemodialysis and artificial liver support therapy were performed with comprehensive medical treatments and the course of the successful rescuing the patient was analyzed. Through the hospitalization of about two mouths the patient and her neonatus had gotten the best of care in our department and pediatric department separately. Both of them were discharged in good condition. The key points for a successful therapy of the pregnant woman with severe hepatitis are termination of the pregnancy and the control of their various complications. It was suggested that the proper combination of these measures of modern therapy would race against time for renewing of hepatic and renal functions.
    World Journal of Gastroenterology 04/2003; 9(3):631-2. · 2.37 Impact Factor